Article
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
International journal of cancer - 15 Jul 2020
Myers Andrea P, Konstantinopoulos Panagiotis A, Barry William T, Luo Weixiu, Broaddus Russell R, Makker Vicky, Drapkin Ronny, Liu Joyce, Doyle Austin, Horowitz Neil S, Meric-Bernstam Funda, Birrer Michael, Aghajanian Carol, Coleman Robert L, Mills Gordon B, Cantley Lewis C, Matulonis Ursula A, Westin Shannon N
Abstract excerpt
Endometrial cancers have high rates of phosphoinositide 3-kinase (PI3K) pathway alterations. MK-2206 is an allosteric inhibitor of AKT, an effector kinase of PI3K signals. We hypothesized patients with tumors harboring PIK3CA mutations would be more likely to benefit from MK-2206 than those without PIK3CA mutation. A Phase II study was performed in patients with recurrent endometrial cancer; all histologies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.